Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis

Abstract Objective To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID‐19 treatment. Methods A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle–Ottawa sca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Behnam Amani, Bahman Amani, Sara Zareei, Mahsa Zareei
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	2019 novel coronavirus infection 2019‐nCoV infection arbidol coronavirus novel coronavirus umifenovir Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/5c8053bcce894c5ca01afc66ae041c69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c8053bcce894c5ca01afc66ae041c69
record_format	dspace
spelling	oai:doaj.org-article:5c8053bcce894c5ca01afc66ae041c692021-11-12T19:57:14ZEfficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis2050-452710.1002/iid3.502https://doaj.org/article/5c8053bcce894c5ca01afc66ae041c692021-12-01T00:00:00Zhttps://doi.org/10.1002/iid3.502https://doaj.org/toc/2050-4527Abstract Objective To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID‐19 treatment. Methods A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle–Ottawa scale were used to assess the quality of included studies. Meta‐analysis was performed using RevMan 5.3. Results Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non‐antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR‐PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78–1.14) and Day 14 (RR: 1.10; 95% CI: 0.96–1.25), and PCR negative conversion time (PCR‐NCT; mean difference [MD]: 0.74; 95% CI: −0.87 to 2.34), nor secondary outcomes (p > .05). However, arbidol was associated with higher adverse events (RR: 2.24; 95% CI: 1.06–4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes (p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR‐PCR on Day 7 and PCR‐NCT (p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes (p > .05). No remarkable therapeutic effect was observed between arbidol and other agents (p > .05). Conclusion The present meta‐analysis showed no significant benefit of using arbidol compared with non‐antiviral treatment or other therapeutic agents against COVID‐19 disease. High‐quality studies are needed to establish the efficacy and safety of arbidol for COVID‐19.Behnam AmaniBahman AmaniSara ZareeiMahsa ZareeiWileyarticle2019 novel coronavirus infection2019‐nCoV infectionarbidolcoronavirusnovel coronavirusumifenovirImmunologic diseases. AllergyRC581-607ENImmunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1197-1208 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	2019 novel coronavirus infection 2019‐nCoV infection arbidol coronavirus novel coronavirus umifenovir Immunologic diseases. Allergy RC581-607
spellingShingle	2019 novel coronavirus infection 2019‐nCoV infection arbidol coronavirus novel coronavirus umifenovir Immunologic diseases. Allergy RC581-607 Behnam Amani Bahman Amani Sara Zareei Mahsa Zareei Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
description	Abstract Objective To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID‐19 treatment. Methods A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle–Ottawa scale were used to assess the quality of included studies. Meta‐analysis was performed using RevMan 5.3. Results Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non‐antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR‐PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78–1.14) and Day 14 (RR: 1.10; 95% CI: 0.96–1.25), and PCR negative conversion time (PCR‐NCT; mean difference [MD]: 0.74; 95% CI: −0.87 to 2.34), nor secondary outcomes (p > .05). However, arbidol was associated with higher adverse events (RR: 2.24; 95% CI: 1.06–4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes (p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR‐PCR on Day 7 and PCR‐NCT (p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes (p > .05). No remarkable therapeutic effect was observed between arbidol and other agents (p > .05). Conclusion The present meta‐analysis showed no significant benefit of using arbidol compared with non‐antiviral treatment or other therapeutic agents against COVID‐19 disease. High‐quality studies are needed to establish the efficacy and safety of arbidol for COVID‐19.
format	article
author	Behnam Amani Bahman Amani Sara Zareei Mahsa Zareei
author_facet	Behnam Amani Bahman Amani Sara Zareei Mahsa Zareei
author_sort	Behnam Amani
title	Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
title_short	Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
title_full	Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
title_fullStr	Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
title_full_unstemmed	Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
title_sort	efficacy and safety of arbidol (umifenovir) in patients with covid‐19: a systematic review and meta‐analysis
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/5c8053bcce894c5ca01afc66ae041c69
work_keys_str_mv	AT behnamamani efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis AT bahmanamani efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis AT sarazareei efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis AT mahsazareei efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis
_version_	1718430318765015040

Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis

Ejemplares similares